1209012-91-8

Basic information

• Product Name: methyl ((2,3-difluorobenzyl) 5-fluoroacetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate
• Synonyms: methyl ((2,3-difluorobenzyl) 5-fluoroacetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate
• CAS NO: 1209012-91-8
• Molecular Weight: 618.521
• Mol File: 1209012-91-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl ((2,3-difluorobenzyl) 5-fluoroacetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl ((2,3-difluorobenzyl) 5-fluoroacetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate(1209012-91-8)
• EPA Substance Registry System: methyl ((2,3-difluorobenzyl) 5-fluoroacetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosid)onate(1209012-91-8)

Safety Data

• Hazardous Substances Data: 1209012-91-8(Hazardous Substances Data)

Upstream product

• 75853-18-8 (2,3-difluoro-phenyl)-methanol 
• 1209012-87-2 methyl (methyl 5-fluoroacetamido-4,7,8-tri-O-acetyl-9-azido-3,5,9-trideoxy-2-thio-D-glycero-α-D-galacto-2-nonulopyranosid)onate 

Relevant articles and documents

From the ganglioside GQ1bα to glycomimetic antagonists of the myelin- associated glycoprotein (MAG)

The tetrasaccharide 4, a substructure of ganglioside GQ1bα, shows a remarkable affinity for the myelinassociated glycoprotein (MAG) and was therefore selected as starting point for a lead optimization program. In our search for structurally simplified and pharmacokinetically improved mimics of 4, antagonists with modifications of the core disaccharide Galβ (1-3)GalNAc, as well as the terminal α (2-3)- and the internal α (2-6)-linked neuraminic acid were synthesized and tested in target-based binding assays. Compared to the reference tetrasaccharide 4, the most potent antagonist 17 exhibits a 360-fold improved affinity. Furthermore, pharmacokinetic parameters such as stability in the cerebrospinal fluid, logD and permeation through the BBB indicate the drug-like properties of antagonist 17. Schweizerische Chemische Gesellschaft.